- Pieris Pharmaceuticals Inc PIRS has announced the development of PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor to treat idiopathic pulmonary fibrosis (IPF).
- The Company will also receive a €14.2 million (approximately $17 million) grant from the Bavarian Ministry of Economic Affairs, Regional Development, and Energy to research and develop PRS-220 for post-acute COVID-19 pulmonary fibrosis, also known as pulmonary fibrosis secondary to COVID-19 or "long COVID."
- Clinical development of the program for both indications is expected to begin next year.
- Price Action: PIRS shares are up 12.8% at $4.93 during the premarket session on the last check Friday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
